Reboxetine as an optional treatment for hyperkinetic conduct disorder: A prospective open-label trial

Tamar Mozes, Gal Meiri, Galit Ben-Amity, Michal Sabbagh, Abraham Weizman

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Background and Purpose: Hyperkinetic conduct disorder (HCD) has been identified as a common psychiatric diagnosis among children and adolescents. This disorder affects many life aspects of both child and family. The aim of this study was to examine the efficacy of the selective norepinephrine reuptake inhibitor (SNRI), reboxetine, in treating children with HCD and its influence on associated symptoms, such as aggressiveness, impulsivity, anxiety, and depression. Methods: Fifteen children, 5-14 years of age, diagnosed with HCD, participated in a 12-week, prospective, open-label trial with reboxetine (4-8 mg/d). They were examined for changes in: ADHD symptoms, as measured by the Conners Abbreviated (10-item) Teacher Rating Scale, aggression, as measured by the Yudofsky Overt Aggression Scale (OAS), impulsivity, as measured by the Plutchik impulsivity scale (IS), anxiety, as measured by the Revised Children's Manifest Anxiety Scale (RCMAS), and depressive mood, as measured by the Hamilton Rating Scale for Depression (HAM-D). Results: There was a significant symptomatic improvement for HCD symptoms and associated symptoms. Conclusion: Our findings suggest that reboxetine may be effective in the treatment of HCD and associated symptoms.

Original languageEnglish
Pages (from-to)259-269
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume15
Issue number2
DOIs
StatePublished - 1 Apr 2005

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Reboxetine as an optional treatment for hyperkinetic conduct disorder: A prospective open-label trial'. Together they form a unique fingerprint.

Cite this